Zusammenfassung
Viele Glomerulonephritiden zählen zu den sog. seltenen Erkrankungen. Dies gilt selbst für häufigere Formen. Sie sind jedoch volkswirtschaftlich hoch bedeutsam, da sie oft junge Menschen betreffen. So stellt beispielsweise die Immunglobulin-A-Nephropathie (IgAN) den häufigsten Grund für ein terminales Nierenversagen im jungen Erwachsenenalter dar. Dieser Beitrag beleuchtet den heutigen Kenntnisstand zur Pathogenese, Klinik und Therapie der häufigsten europäischen Glomerulonephritisformen. Ein besonderer Fokus liegt dabei auf neuesten Erkenntnissen zu IgAN, membranöser Glomerulonephritis, Minimal-change-Nephropathie und fokal-segmentaler Glomerulosklerose.
Abstract
Many forms of glomerulonephritis, even the more common types belong to the so-called rare diseases; however, they are very important, for example with respect to health economics as they often affect young people. An example is immunoglobulin A (IgA) nephropathy, which is the most common cause of end stage renal disease in young adults. This review summarizes the current knowledge on the pathogenesis, clinical presentation and therapy of the most common European types of glomerulonephritis with a special focus on the most recently acquired knowledge on IgA nephropathy, membranous glomerulonephritis, minimal change nephropathy and focal segmental glomerulosclerosis (FSGS).
Literatur
Floege J, Eitner F (2011) Current therapy for IgA nephropathy. J Am Soc Nephrol 22:1785–1794
Floege J (2011) The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 58:992–1004
Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196
o A (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2(Suppl 2):139–274
Rauen T, Eitner F, Fitzner C et al (o J) Intensive supportive therapy plus immunosuppression in IgA nephropathy. (Im Druck)
Beck LH Jr, Bonegio RG, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21
Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371:2277–2287
Hoxha E, Kneissler U, Stege G et al (2012) Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82:797–804
(o A) (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:142
Clement LC, Avila-Casado C, Mace C et al (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17:117–122
Pollak MR (2014) Familial FSGS. Adv Chronic Kidney Dis 21:422–425
Einhaltung ethischer Richtlinien
Interessenkonflikt. Beratertätigkeit Fa. Pharmalink
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Floege, J. Glomerulonephritiden. Internist 56, 1277–1287 (2015). https://doi.org/10.1007/s00108-015-3781-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-015-3781-1
Schlüsselwörter
- Primäre Glomerulonephritis
- IgA-Nephropathie
- Membranöse Glomerulonephritis
- Minimal-change-Nephropathie
- Fokal-segmentale Glomerulosklerose